ORMP - Oramed Pharmace Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-0.42%) AMD (-2.77%) DGAZ (7.39%) FB (-1.34%) BABA (-1.85%) MSFT (-1.53%) TEVA (-1.05%) TSLA (-1.97%) TTWO (1.4%) AVGR (-1.86%) AMZN (-0.79%) IPGP (-2.13%) INCY (0.43%) IBM (0.24%) GRPN (0.3%) GNPX (12.31%) FLR (3.56%) ETSY (2.28%) ENDP (-2.4%) DXC (2.02%) DIS (-0.66%) CNC (0%) CME (0%) CI (0%) CCJ (-1.52%)

ORMP - Oramed Pharmaceutica...

$4.95 0[0%]

15 mins delayed data

People also watch : PSTI | SNY | NVO | RARE | ROSGQ | CGEN

+Watchlist

1 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$4.95	Open
Volume		Market Cap	52.66M
Yield		Last Dividend

Day

52 Week

Oramed Patent in Europe to be Granted fo...	01/28/20
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ...

Oramed Elects Dr. Alexander Fleming to S...	01/23/20
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on t...

Oramed Appoints Dr. Jay Skyler to Scient...	01/21/20
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical comp...

Oramed Pharmaceuticals : Quarterly repor...	01/09/20
Salaryof the Original Agreement, the following paragraph is hereby added: As of January 1, 2020, the Executive shall be entitled to a gross monthly sa...

Oramed Pharmaceuticals Issues Letter to ...	01/09/20
NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical compa...

The Daily Biotech Pulse: Axovant Surges ...	12/20/19
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs D...

ORAMED PHARMACEUTICALS INC. : Stock Mark...	12/06/19
ORAMED PHARMACEUTICALS INC. : News, information and stories for ORAMED PHARMACEUTICALS INC. \| Nasdaq: ORMP \| Nasdaq

Oramed Appoints Dr. Arie Mayer to Board ...	12/05/19
NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical compa...

Oramed to Present a Scientific Poster at...	12/02/19
NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical c...

Oramed Provides Highlights and Data From...	11/19/19
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical comp...

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP...	08/16/19
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also???

Oramed nabs new patent in U.S.	03/28/19
No summary available.

Oramed up 11% on oral insulin studies in...	03/26/19
No summary available.

The Math Behind Oramed's Oral Insulin Su...	02/20/19
No summary available.

CNBC article highlights $35B market oppo...	12/31/18
No summary available.

CNBC article highlights $35B market oppo...	12/31/18
No summary available.

ANALYST RATINGS

1 analyst ratings (Last 6 months)

100.00 %

Strong Buy + Buy

Price Target (PT)

Buy rating	09/11/19
Ladenburg Thalmann initiates coverage with Buy rating and announces Price Target of $7.00

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $ORMP

Service Name	Trader	% Success
Tech Trades	Ravi	89.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.